This 2018 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and. It drew over 900 professionals representing large Pharmas, Biotechs, Contract Research Organizations and multiple regulatory agencies from around the world, from the global bioanalytical. She was quickly promoted to Associate Principal Scientist and has transitioned to the role of scientific lead for the protein bioanalysis group within discovery bioanalytics, responsible for the development and application of LC–MS to support biopharmaceutical PK studies and biomarker analysis. The PhD Data Task Force was formed to better understand the current state of PhD scientists in the clinical laboratory workforce and collect up-to-date information on the training and certification of these laboratorians. Over the past 8 years, Bioanalysis Zone have supported and recognized outstanding early-career researchers in the field of bioanalysis. Since its initiation, there have been seven winners with this year’s winner soon to be announced. The first studies measuring drugs in biological fluids were carried out to determine possible overdosing as part of the new science of forensic medicine/ toxicology. The 2018 12th Workshop on Recent Issues in Bioanalysis (12th WRIB) took place in Philadelphia, PA, USA on April 9-13, 2018 with an attendance of over 900 representatives from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. Due to its length, the 2018 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 1) covers the recommendations for LC-MS for small molecules, peptides, oligonucleotides and small molecule biomarkers. Due to its length, the 2018 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 1) covers the recommendations for LC–MS for small molecules, peptides, oligonucleotides and small molecule biomarkers. As amended, Section 493.1443 (3) (i) (A) now requires an “earned doctoral degree in a chemical, biological, clinical or medical laboratory science, or medical technology.”.